HOME >> MEDICINE >> NEWS
Cancer researcher Susan Horwitz wins Alpert prize for Taxol work

BOSTON-Susan Band Horwitz, Ph.D., the Falkenstein Professor of Cancer Research and Co-Chair of the Department of Molecular Pharmacology at the Albert Einstein College of Medicine, will today be awarded the 17th annual Warren Alpert Foundation Prize. The foundation recognizes Dr. Horwitz, a molecular pharmacologist, for her seminal contributions to the understanding of how the antitumor agent Taxol inhibits the growth of cancer cells. Her research helped pave the way for studies leading to approval of the plant compound for the treatment of ovarian, breast and lung cancers. The foundation will award Dr. Horwitz a $150,000 prize.

"One thing that Mr. Alpert stipulated when he developed this prize was that it should go to someone who had already made major contributions to helping patients. The impact of Susan's work has been quite extraordinary in the cancer field," said Professor Dominick Purpura, MD, Dean of Albert Einstein College of Medicine, who nominated Dr. Horwitz for the prize. In fact, earlier this year, shortly after Dr. Horwitz was selected as winner of the prize, she was acknowledged by her peers for her contributions to cancer research when she was elected to the National Academy of Sciences.

In the US, Taxol was first approved by the Food and Drug Administration (FDA) for the treatment of refractory ovarian cancer in 1992. Approval for metastatic breast cancer followed in 1994, and more recently for non-small cell lung cancer in 1999. "Taxol has become one of the most valuable cytotoxic chemotherapeutic agents we have in clinical oncology. It has proven effective in ovarian, breast, lung, and head and neck cancer and it has contributed immensely to the quality of life of cancer patients," said Larry Shulman, associate professor of medicine at the Dana-Farber Cancer Institute, Boston. The drug has been used in well over a million patients worldwide.

In 1977, Dr. Horwitz was approached by the National Cancer Institute to study the
'"/>

Contact: john_lacey@hms.harvard.edu
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
22-Jun-2005


Page: 1 2 3

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. Cancer research summaries
3. Cancer on the agenda of the Portuguese EU Council Presidency
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
6. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
7. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
8. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
9. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
10. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research
11. Cancer-fighting foods, supplements explored in day-long symposium, March 25

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... FL (PRWEB) , ... February 22, 2017 , ... Gevir, ... from deer antler velvet, announced its products are coming soon to Amazon.com, the world’s ... and Shelley Thomson as a means to develop an effective natural treatment for Shelley’s ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... a contract to Quality Insights to help small practices in Delaware, New Jersey, ... Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017  Allergan plc (NYSE: AGN), ... be a Gold sponsor of the Alzheimer,s Foundation ... Tour." This tour commemorates AFA,s15 years of educating ... and programs. The tour will include AFA,s free ... and displays of the AFA Quilt to Remember. ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... NEW YORK , February 22, 2017 ... half of the 50 states in the U.S. have now legalized ... Brazil , Canada , ... , Portugal , Uruguay ... steps to legalize or decriminalize cannabis in the last two years. ...
Breaking Medicine Technology:
Cached News: